NEXGEL reports FY2023 revenue $4.1M (+99.7% YoY); net loss narrows to $3.2M

NEXGEL, INC.

2024-Q1 EPS reported -$0.14 revenue$1,266,000

Revenue $4.1M for FY2023, up 99.7% YoY; Q4 revenue $1.1M, up 110% YoY.
Net loss $3.2M vs $4.7M prior year; gross profit margin improved to 15.2% from 12.5%.
Ended FY2023 with $2.7M cash; subsequent $1M insider-led direct offering closed.
Q1 2024 revenue guided to ~$1.25M, excluding $176K AbbVie deposit.
Key operational milestones: JV with CG Converting, AbbVie gel pad supply agreement, Kenkoderm acquisition.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEXGEL, INC. reported the fourth quarter and year ended December 31, 2023 results: revenue $4.1 million, net income Net loss for the year ended December 31, 2023, was $3.2 million.

Period: the fourth quarter and year ended December 31, 2023
Revenue: $4.1 million
Net income: Net loss for the year ended December 31, 2023, was $3.2 million
Result: reported results

Exact text from the filing

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

NEXGEL, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-012173

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.